$555 Million is the total value of TRV GP II, LLC's 5 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BPMC | New | BLUEPRINT MEDICINES CORPORATION | $185,038,000 | – | 2,453,753 | +100.0% | 33.32% | – |
| JNCE | New | JOUNCE THERAPEUTICS, INC. | $130,437,000 | – | 10,230,349 | +100.0% | 23.49% | – |
| MYOK | New | MYOKARDIA, INC. | $121,463,000 | – | 2,885,104 | +100.0% | 21.88% | – |
| SAGE | New | SAGE THERAPEUTICS, INC. | $90,247,000 | – | 547,916 | +100.0% | 16.25% | – |
| ALNA | New | ALLENA PHARMACEUTICALS, INC. | $28,077,000 | – | 2,790,964 | +100.0% | 5.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Mark Levin #1
- Kevin P. Starr #2
- Robert I. Tepper #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| JOUNCE THERAPEUTICS, INC. | 20 | Q3 2022 | 100.0% |
| ALLENA PHARMACEUTICALS, INC. | 19 | Q2 2022 | 24.4% |
| BLUEPRINT MEDICINES CORPORATION | 6 | Q1 2019 | 47.1% |
| REVOLUTION MEDICINES, INC. | 5 | Q1 2021 | 55.4% |
| SAGE THERAPEUTICS, INC. | 5 | Q4 2018 | 16.3% |
| MYOKARDIA, INC. | 2 | Q1 2018 | 21.9% |
View TRV GP II, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-05 |
| 4 | 2021-09-17 |
| 13F-HR | 2021-08-11 |
| 4 | 2021-06-14 |
| 4 | 2021-06-07 |
| 4 | 2021-05-27 |
View TRV GP II, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.